Basal Cell Carcinoma Treatment Yielded Positive Results
In a mid-stage trial, an experimental drug showed promise for clearing skin lesions in patients with basal cell carcinoma.
Updated on Sept. 30, 2026 in Cancer
Live Poll
Would you prefer non-surgical options over traditional surgery for treating common skin cancers?
Highlight Therapeutics has reported positive phase 2b results for its experimental drug, BO-112, in patients with basal cell carcinoma. The study found that 61% of participants achieved a visual and pathological response at 24 weeks.
Why it matters
These results provide clinical validation for BO-112 as a potential treatment option, potentially expanding the therapeutic landscape for patients with resectable basal cell carcinoma. The data supports the company's decision to advance the drug into late-stage development.
In a phase 2b trial of 46 patients with resectable basal cell carcinoma, 61% achieved visual and pathological response at 24 weeks. This preliminary study noted grade 1 adverse events in 91% of participants, with 88% of these events resolving within three days.
The players
Highlight Therapeutics
A biotechnology company focused on developing nanoparticle-based therapies to stimulate immune responses in tumors.
The details
BO-112 functions as a double-stranded RNA nanoparticle designed to convert immunologically 'cold' tumors into 'hot' tumors. By activating innate antiviral sensing pathways, the drug induces tumor cell death and triggers a targeted adaptive immune response against the cancer cells.
Timeline
Week 24 was the endpoint for measuring visual and pathological responses.
September 30, 2026, was when the trial results were presented at the EADV congress in Vienna.
Health Landscape
This development reflects an ongoing effort to identify effective, localized treatments for skin cancers beyond established surgical and systemic interventions. It builds upon the regulatory precedents set by the 2021 FDA approval of Libtayo for advanced basal cell carcinoma.
Patients with basal cell carcinoma should discuss available treatment pathways with their dermatologist or oncologist to understand if they are candidates for clinical trials. Monitoring any skin lesions for changes remains essential, as this study specifically targeted resectable tumors.
The takeaway
The phase 2b trial suggests that BO-112 may offer a new way to treat specific types of basal cell carcinoma. If you are currently managing skin cancer, speak with your physician about the latest clinical trial developments that might be relevant to your specific diagnosis.
Further reading
For more information on current treatment trends, visit our Cancer section.
Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.
Live Poll
Would you prefer non-surgical options over traditional surgery for treating common skin cancers?
